ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Peak & Trough levels for TRT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 193434" data-attributes="member: 13851"><p>The small pilot study was done by my urologist in 2005.</p><p></p><p>It was posted up numerous times in 2006 and the years following on the numerous steroid forums when news first hit the scene along with the first pilot study ever done (Canada) using subcutaneous T injections. <strong>Subcutaneous administration of testosterone A pilot study report (2006) </strong>posted above.</p><p></p><p></p><p></p><p></p><p><strong>STABLE TESTOSTERONE LEVELS ACHIEVED WITH SUBCUTANEOUS TESTOSTERONE INJECTIONS (2005)</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Objectives:</strong> The preferred technique of androgen replacement has been intramuscular (IM) testosterone, but wide variations in testosterone levels are often seen. <strong><u>Subcutaneous (SC) testosterone injection is a novel approach; however, its physiological effects are unclear</u>. <u>We, therefore, investigated the sustainability of stable testosterone levels using SC therapy</u>.</strong></p><p><strong></strong></p><p><strong>Patients and methods:</strong> <strong><u>Between May and September 2005</u></strong>, we conducted a small pilot study involving 10 male patients with symptomatic late-onset hypogonadism.</p><p></p><p>Every patient had been stable on TE 200 mg IM for 1 year. <strong><u>Patients were instructed to self-inject with testosterone enanthate (TE) 100 mg SC (DELATESTRYL 200 mg/cc, Theramed Corp, Canada) into the anterior abdomen once weekly</u>.</strong> Some patients were down-titrated to 50 mg based on their total testosterone (T) at 4 weeks.</p><p></p><p><strong>Informed consent was obtained as SC testosterone administration is not officially approved by Health Canada.</strong> <strong><u>T levels were measured before and 24 hours after injection during weeks 1, 2, 3, and 4, and 96 hours after injection in weeks 6 and 8</u>. </strong></p><p></p><p>At week 12, PSA, CBC, and T levels were measured however; the week 12 data are still being collected.</p><p></p><p><strong>Results:</strong> <strong><u>Prior to initiation of SC therapy, T was 19.14+3.48 nmol/l, hemoglobin 15.8+1.3 g/dl, hematocrit 0.47+0.02, and PSA 1.05+0.65 ng/ml</u>. <u>During the first 4 weeks, there was a steady increase in pre-injection T from 19.14+3.48 to 23.89+9.15 nmol/l (p¼0.1)</u>. <u>However, after 8 weeks the post-injection T (25.77+7.67 nmol/l) remained similar to that of week 1 (27.46+12.91 nmol/l)</u>.</strong> Patients tolerated this therapy with no adverse effects.</p><p></p><p><strong>Conclusions:</strong> <strong><u>A once-week SC injection of 50-100 mg of TE appears to achieve sustainable and stable levels of physiological T</u>.</strong> This technique offers fewer physician visits and the use of a smaller quantity of medication, thus lower costs. However, the long term clinical and physiological effects of this therapy need further evaluation.</p></blockquote><p></p>
[QUOTE="madman, post: 193434, member: 13851"] The small pilot study was done by my urologist in 2005. It was posted up numerous times in 2006 and the years following on the numerous steroid forums when news first hit the scene along with the first pilot study ever done (Canada) using subcutaneous T injections. [B]Subcutaneous administration of testosterone A pilot study report (2006) [/B]posted above. [B]STABLE TESTOSTERONE LEVELS ACHIEVED WITH SUBCUTANEOUS TESTOSTERONE INJECTIONS (2005) Objectives:[/B] The preferred technique of androgen replacement has been intramuscular (IM) testosterone, but wide variations in testosterone levels are often seen. [B][U]Subcutaneous (SC) testosterone injection is a novel approach; however, its physiological effects are unclear[/U]. [U]We, therefore, investigated the sustainability of stable testosterone levels using SC therapy[/U]. Patients and methods:[/B] [B][U]Between May and September 2005[/U][/B], we conducted a small pilot study involving 10 male patients with symptomatic late-onset hypogonadism. Every patient had been stable on TE 200 mg IM for 1 year. [B][U]Patients were instructed to self-inject with testosterone enanthate (TE) 100 mg SC (DELATESTRYL 200 mg/cc, Theramed Corp, Canada) into the anterior abdomen once weekly[/U].[/B] Some patients were down-titrated to 50 mg based on their total testosterone (T) at 4 weeks. [B]Informed consent was obtained as SC testosterone administration is not officially approved by Health Canada.[/B] [B][U]T levels were measured before and 24 hours after injection during weeks 1, 2, 3, and 4, and 96 hours after injection in weeks 6 and 8[/U]. [/B] At week 12, PSA, CBC, and T levels were measured however; the week 12 data are still being collected. [B]Results:[/B] [B][U]Prior to initiation of SC therapy, T was 19.14+3.48 nmol/l, hemoglobin 15.8+1.3 g/dl, hematocrit 0.47+0.02, and PSA 1.05+0.65 ng/ml[/U]. [U]During the first 4 weeks, there was a steady increase in pre-injection T from 19.14+3.48 to 23.89+9.15 nmol/l (p¼0.1)[/U]. [U]However, after 8 weeks the post-injection T (25.77+7.67 nmol/l) remained similar to that of week 1 (27.46+12.91 nmol/l)[/U].[/B] Patients tolerated this therapy with no adverse effects. [B]Conclusions:[/B] [B][U]A once-week SC injection of 50-100 mg of TE appears to achieve sustainable and stable levels of physiological T[/U].[/B] This technique offers fewer physician visits and the use of a smaller quantity of medication, thus lower costs. However, the long term clinical and physiological effects of this therapy need further evaluation. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Peak & Trough levels for TRT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top